PPARG and fatty liver disease: Indeed, the PPARγ agonist pioglitazone and PPARα fenofibrate reduced atherosclerosis and hepatic steatosis in mice lacking both ApoE and Farnesoid x receptor (FXR) (439), which modeled NASH and atherosclerosis simultaneously.